Metagenomi (MGX) director Jian Irish awarded options and 46,000 RSUs
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Metagenomi Therapeutics director and officer Jian Irish reported equity awards and updated holdings. She received a stock option covering 276,000 shares of common stock at an exercise price of $1.34 per share, expiring on March 31, 2036, with 25% vesting on April 1, 2027 and the rest in 36 monthly installments. She also received 46,000 restricted stock units, 25% of which vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments. Following these awards, she holds 379,770 shares of common stock directly, and additional shares are held indirectly by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish and the Jian Irish 2023 Irrevocable Trust, where she disclaims beneficial ownership except to the extent of her pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Irish Jian
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 276,000 | $0.00 | -- |
| Grant/Award | Common Stock | 46,000 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 276,000 shares (Direct);
Common Stock — 379,770 shares (Direct);
Common Stock — 292,714 shares (Indirect, By Trust)
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
Key Figures
Option grant size: 276,000 shares
Option exercise price: $1.34 per share
Option expiration: March 31, 2036
+4 more
7 metrics
Option grant size
276,000 shares
Stock option covering common stock granted on April 1, 2026
Option exercise price
$1.34 per share
Exercise price for 276,000-share stock option
Option expiration
March 31, 2036
Expiration date of granted stock option
RSU grant size
46,000 shares
Restricted stock units granted as of April 1, 2026
Direct common stock holdings
379,770 shares
Direct ownership following reported transactions
Indirect trust holding (Bruce Irish Trust)
292,714 shares
Common stock held by Bruce Irish 2023 Irrevocable Trust FBO Jian Irish
Indirect trust holding (Jian Irish Trust)
292,713 shares
Common stock held by Jian Irish 2023 Irrevocable Trust
Key Terms
restricted stock units ("RSUs"), Irrevocable Trust, pecuniary interest, Section 16
4 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Irrevocable Trust financial
"Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish."
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
pecuniary interest financial
"The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein"
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did Jian Irish report for Metagenomi Therapeutics (MGX)?
Jian Irish reported equity awards consisting of a stock option for 276,000 shares at $1.34 per share and 46,000 restricted stock units. These are compensation-related grants, not open-market purchases or sales, and update her direct and indirect ownership position in Metagenomi Therapeutics.
How large is the stock option grant to Jian Irish at Metagenomi Therapeutics (MGX)?
The reported stock option grant covers 276,000 shares of Metagenomi Therapeutics common stock with an exercise price of $1.34 per share. This option vests over time, beginning in 2027, and expires on March 31, 2036, reflecting long-term, service-based compensation.
What are the vesting terms of Jian Irish’s RSUs in Metagenomi Therapeutics (MGX)?
The 46,000 restricted stock units granted to Jian Irish vest over several years. According to the disclosure, 25% vest on June 5, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to her continued service with Metagenomi Therapeutics.
Are Jian Irish’s reported Metagenomi Therapeutics (MGX) transactions open-market buys or sells?
The reported transactions are equity awards, not open-market trades. They include a stock option grant and restricted stock units granted at a price of $0.00 per share as compensation, with vesting schedules tied to continued service at Metagenomi Therapeutics.